The Mayo Clinic Cancer Center (MCCC) is poised to continue to provide an outstanding training experience for academic oncologists and translational cancer researchers. This institution remains at the epicenter of high-quality, practice-changing cancer clinical/translational trials. The MCCC is a National Cancer Institute (NCI)-designated comprehensive cancer center and is in its 36th year of continuous funding. Its funding portfolio includes an NCI-funded Phase I grant;a Phase II contract;7 SPORE's (prostate, pancreas, breast, brain, ovary, multiple myeloma, and lymphoma);and multiple investigator-initiated grants. It maintains strong ties to national cancer cooperative groups, including the North Central Cancer Treatment Group, for which the Mayo Clinic is the sole research base, and the American College of Surgeons Cooperative Group. The Mayo Graduate School of Medicine is one of the largest training programs in the world, educating 1400+ physicians annually in over 100 specialties. Thus, the MCCC seeks to renew the """"""""Paul Calabresi Program in Clinical and Translational Research at the Mayo Clinic,"""""""" requesting 7 positions/year. The MCCC has been privileged to hold this award since 2001. To date, all 21 scholars hold academic appointments, 67% have secured other funding, some hold leadership positions in academic oncology, and each has published in cancer therapeutics, cumulatively amassing 700+ publications. In this application, as before, scholars must focus on 1 of 6 research tracks that align with MCCC Programs: Gastrointestinal Malignancies, Genitourinary Malignancies, Hematology, Neuro-oncology, Novel Therapeutics, or Women's Cancers. Multidisciplinary teams will work with each scholar as he/she completes coursework, embarks upon hands-on research, and strives for career independence. Co-principal investigators, Aminah Jatoi, M.D., who is Associate Director for Education and Training for the MCCC, and Lynn Hartmann, M.D., who has overseen this program since its inception, will together lead this training program. An Advisory Committee comprised of 7 MCCC leaders will provide oversight. The MCCC seeks to train the next generation of investigators to enable them to conduct cutting- edge, hypothesis-driven research in cancer therapeutics.

Public Health Relevance

The Mayo Clinic Cancer Center (MCCC) is a National Cancer Institute (NCI)-designated comprehensive cancer center and is in its 36th year of continuous funding. It remains at the epicenter of high-quality, practice-changing cancer clinical/translational trials. The MCCC now seeks to renew the Paul Calabresi Program in Clinical and Translational Research at the Mayo Clinic in order to train the next generation of investigators who will conduct cutting-edge, hypothesis-driven research in cancer therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12CA090628-14
Application #
8692666
Study Section
Special Emphasis Panel (ZCA1-RTRB-E (J1))
Program Officer
Damico, Mark W
Project Start
2001-09-25
Project End
2016-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
14
Fiscal Year
2014
Total Cost
$899,782
Indirect Cost
$84,000
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Leventakos, Konstantinos; Peikert, Tobias; Midthun, David E et al. (2017) Management of Multifocal Lung Cancer: Results of a Survey. J Thorac Oncol 12:1398-1402
Ruella, Marco; Klichinsky, Michael; Kenderian, Saad S et al. (2017) Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. Cancer Discov 7:1154-1167
Cotter, Thomas G; Burger, Kelli N; Devens, Mary E et al. (2017) Long-term Follow-up of Patients Having False-Positive Multitarget Stool DNA Tests after Negative Screening Colonoscopy: The LONG-HAUL Cohort Study. Cancer Epidemiol Biomarkers Prev 26:614-621
Tasian, Sarah K; Kenderian, Saad S; Shen, Feng et al. (2017) Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. Blood 129:2395-2407
Tsang, Mazie; Parikh, Sameer A (2017) A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia. Curr Hematol Malig Rep 12:29-38
Ding, Wei; LaPlant, Betsy R; Call, Timothy G et al. (2017) Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood 129:3419-3427
Tabibian, James H; Kenderian, Saad S (2017) The Microbiome and Immune Regulation After Transplantation. Transplantation 101:56-62
Finnes, Heidi D; Chaffee, Kari G; Call, Timothy G et al. (2017) Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. Leuk Lymphoma 58:1376-1383
Ruella, M; Kenderian, S S; Shestova, O et al. (2017) Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms. Leukemia 31:246-248
Paludo, Jonas; Fritchie, Karen; Haddox, Candace L et al. (2017) Extraskeletal Osteosarcoma: Outcomes and the Role of Chemotherapy. Am J Clin Oncol :

Showing the most recent 10 out of 228 publications